You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

5276 Results
Document
Sep 2023
Document
Sep 2023
Guidelines and Advice
Status: Current
ID: GL-END-C50-35
Aug 2023
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    trifluridine / tipiracil - In combination with bevacizumab for treatment of metastatic colorectal cancer, according to clinical criteria
New Drug Funding Program
    Bevacizumab (Biosimilar) - In Combination with Trifluridine and Tipiracil for Previously Treated Metastatic Colorectal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
trifluridine / tipiracil,
bevacizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2024
Document
Nov 2023
Statistical Reports
Jan 2024
Document
Nov 2023
Guidelines and Advice
Status: Current
ID: GL-END 3-25
Nov 2023
Document
Nov 2023

Pages